D. Bliuc, N. Nguyen, V. Milch, T. Nguyen, J. Eisman et al., Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women, JAMA, vol.301, issue.5, pp.513-534, 2009.
DOI : 10.1001/jama.2009.50

A. Oleksik, P. Lips, A. Dawson, M. Minshall, W. Shen et al., Health-Related Quality of Life in Postmenopausal Women With Low BMD With or Without Prevalent Vertebral Fractures, Journal of Bone and Mineral Research, vol.50, issue.Suppl, pp.1384-92, 2000.
DOI : 10.1359/jbmr.2000.15.7.1384

C. Cooper, E. Atkinson, S. Jacobsen, O. Fallon, W. Melton et al., Population-Based Study of Survival after Osteoporotic Fractures, American Journal of Epidemiology, vol.137, issue.9, pp.1001-1006, 1993.
DOI : 10.1093/oxfordjournals.aje.a116756

J. Cauley, D. Thompson, K. Ensrud, J. Scott, and D. Black, Risk of Mortality Following Clinical Fractures, Osteoporosis International, vol.11, issue.7, pp.556-61, 2000.
DOI : 10.1007/s001980070075

C. Rosen, L. De-groot, P. Beck-peccoz, G. Chrousos, K. Dungan et al., The Epidemiology and Pathogenesis of Osteoporosis, Inc, 2000.

K. Briot, M. Maravic, and C. Roux, Changes in number and incidence of hip fractures over 12years in France, Bone, vol.81, pp.131-138, 2015.
DOI : 10.1016/j.bone.2015.07.009

D. Curran, M. Maravic, P. Kiefer, V. Tochon, and P. Fardellone, Epidemiology of osteoporosisrelated fractures in France: a literature review, Jt Bone Spine Rev Rhum, 2010.

K. Briot, B. Cortet, T. Thomas, M. Audran, H. Blain et al., 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis, Joint Bone Spine, vol.79, issue.3, pp.304-317
DOI : 10.1016/j.jbspin.2012.02.014

J. Reginster, Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs, pp.65-78, 2011.

P. Sambrook, I. Cameron, J. Chen, L. March, J. Simpson et al., Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study, Osteoporosis International, vol.24, issue.9, pp.2551-2557, 2011.
DOI : 10.1007/s00198-010-1444-6

K. Lyles, C. Colón-emeric, J. Magaziner, J. Adachi, C. Pieper et al., Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture, N Engl J Med, vol.357, p.40967, 2007.

D. Black, D. Bauer, A. Schwartz, S. Cummings, and C. Rosen, Continuing Bisphosphonate Treatment for Osteoporosis ??? For Whom and for How Long?, New England Journal of Medicine, vol.366, issue.22, 2015.
DOI : 10.1056/NEJMp1202623

D. Black, A. Schwartz, K. Ensrud, J. Cauley, S. Levis et al., Effects of Continuing or Stopping Alendronate After 5 Years of Treatment, JAMA, vol.296, issue.24, pp.2927-2965, 2006.
DOI : 10.1001/jama.296.24.2927

A. Juby, D. Geus-wenceslau, and C. , Evaluation of Osteoporosis Treatment in Seniors after Hip Fracture, Osteoporosis International, vol.13, issue.3, pp.205-215, 2002.
DOI : 10.1007/s001980200015

H. Kamel, Underutilization of Calcium and Vitamin D Supplements in an Academic Long-Term Care Facility, Journal of the American Medical Directors Association, vol.5, issue.2, pp.98-100
DOI : 10.1016/S1525-8610(04)70062-6

H. K. Kamel and E. Duthie, The Underuse of Therapy in the Secondary Prevention of Hip Fractures. Drugs Aging, pp.1-10, 2002.

A. Bouvet, B. Sabatier, V. Savoldelli, T. Caruba, and J. Pouchot, Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture, J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis, vol.20, issue.6, pp.347-355, 2014.

M. Andro, A. Coutard, and A. Gentric, Underuse in Elderly Adults: An Underestimated Suboptimal Prescribing, Journal of the American Geriatrics Society, vol.59, issue.8, pp.1582-1585, 2012.
DOI : 10.1111/j.1532-5415.2012.04071.x

L. Giangregorio, A. Papaioannou, A. Cranney, N. Zytaruk, and J. Adachi, Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum, 2006.

H. Kamel, M. Hussain, S. Tariq, H. Perry, and J. Morley, Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture, The American Journal of Medicine, vol.109, issue.4, 2000.
DOI : 10.1016/S0002-9343(00)00457-5

P. Lüthje, I. Nurmi-lüthje, J. Kaukonen, S. Kuurne, H. Naboulsi et al., Undertreatment of osteoporosis following hip fracture in the elderly, Archives of Gerontology and Geriatrics, vol.49, issue.1, 2009.
DOI : 10.1016/j.archger.2008.06.007

C. Klop, D. Gibson-smith, P. Elders, P. Welsing, H. Leufkens et al., Antiosteoporosis drug prescribing after hip fracture in the UK: 2000-2010, Osteoporos Int J Establ Result, 2015.

S. Parikh, M. Brookhart, M. Stedman, J. Avorn, H. Mogun et al., Correlations of nursing home characteristics with prescription of osteoporosis medications, Bone, vol.48, issue.5, pp.1164-1172, 2011.
DOI : 10.1016/j.bone.2011.02.006

G. Turner and A. Clegg, Best practice guidelines for the management of frailty: a British Geriatrics Society, Age UK and Royal College of General Practitioners report. Age Ageing, vol.43, issue.6, pp.744-751, 2014.

C. Colón-emeric, K. Lyles, D. Levine, P. House, A. Schenck et al., Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture, Osteoporosis International, vol.165, issue.20, pp.553-562, 2007.
DOI : 10.1007/s00198-006-0260-5

B. Cortet and O. Bénichou, Adh??rence, observance, persistance, concordance??: prenons-nous en??charge correctement nos patientes ost??oporotiques???, Revue du Rhumatisme, vol.73, issue.9, pp.1-9, 2006.
DOI : 10.1016/j.rhum.2005.09.015

T. Ait-abdesselam, A. Lamacz, S. Titz, G. Micaud, N. Biga et al., Pr??vention secondaire de??l'ost??oporose fracturaire: r??sultats ????un??an d'une fili??re de??prise en??charge des??patients fractur??s, Revue du Rhumatisme, vol.73, issue.10-11, pp.10-111140, 2006.
DOI : 10.1016/j.rhum.2006.10.315

K. Briot, M. Audran, B. Cortet, P. Fardellone, C. Marcelli et al., Vitamine D??: effet osseux et extra-osseux??; recommandations de bon usage, Presse Médicale, 2009.
DOI : 10.1016/j.lpm.2008.08.008

A. Raynaud-simon, Y. Rolland, and J. Souberbielle, Vitamine D chez la personne âgée : pourquoi ? Quand ? Comment ? Nutr Clin Métabolisme, pp.123-132, 2014.

. Pathologie-neurodégénérative-diagnostiquée, MMS : Caractéristiques de déplacement : -Marche (sans aide, avec cannes, avec déambulateur) -Avec fauteuil roulant -Confinement au lit et au fauteuil GIR